DFX Intelligence
Data Factory
Reading the graph
Reading the graph
CRD 161569
NEW YORK, NY
Data as of (this record's last observation) from federal regulator filings. Page built and rebuilt at most every 15 minutes.
| Fund | Type | Reported GAV | As of | Owners | First reported | Status | Form D file |
|---|---|---|---|---|---|---|---|
| RPI INTERNATIONAL HOLDINGS, LP | Private Equity Fund | $2.1B | Mar 30, 2021 | 12 | Feb 15, 2012 | dropped | 021-164855 |
| RPI INTERNATIONAL PARTNERS, LP | Private Equity Fund | $1.8B | Mar 30, 2021 | 2 | Feb 15, 2012 | dropped | n/a |
| RPI US PARTNERS 2019, LP | Private Equity Fund | $1.6B | Mar 28, 2024 | 66 | Mar 27, 2020 | reported | 021-360188 |
| RPI INTERMEDIATE FINANCE PARTNERSHIP, LP | Hedge Fund | $1.5B | Mar 28, 2024 | 40 | Apr 29, 2021 | reported | 021-164855 |
| RPI HOLDINGS, LP | Private Equity Fund | $1.1B | Mar 29, 2018 | 1 | Feb 15, 2012 | dropped | n/a |
| RPI INTERNATIONAL HOLDINGS 2019, LP | Private Equity Fund | $1.0B | Mar 30, 2021 | 1 | Mar 27, 2020 | dropped | 021-360176 |
| RPI US PARTNERS, LP | Private Equity Fund | $858M | Mar 30, 2021 | 14 | Feb 15, 2012 | dropped | 021-164857 |
| RPI US PARTNERS II, LP | Private Equity Fund | $415M | Mar 30, 2021 | 6 | Feb 15, 2012 | dropped | 021-164856 |
| RPI INTERNATIONAL PARTNERS II, LP | Private Equity Fund | $344M | Mar 30, 2021 | 2 | Feb 15, 2012 | dropped | n/a |
| RPS BIOPHARMA HOLDINGS, L.P. | Private Equity Fund | $72.8M | Sep 16, 2019 | 52 | Mar 29, 2018 | dropped | n/a |
| ROYALTY PHARMA CAYMAN HOLDINGS, LP | Private Equity Fund | $61.9M | Mar 30, 2021 | 24 | Feb 15, 2012 | dropped | n/a |
| ROYALTY PHARMA CAYMAN PARTNERS, LP | Private Equity Fund | $61.9M | Mar 30, 2021 | 2 | Feb 15, 2012 | dropped | 021-113469 |
| RPS BIOPHARMA HOLDINGS, LP | Private Equity Fund | $32.8M | Mar 30, 2021 | 52 | Mar 27, 2020 | dropped | 021-284413 |
| RPS BIOPHARMA INVESTMENTS, LP | Private Equity Fund | $29.6M | Mar 30, 2021 | 57 | Mar 29, 2018 | dropped | 021-284414 |
| ROYALTY PHARMA US PARTNERS LP | Private Equity Fund | $20.6M | Mar 30, 2021 | 40 | Feb 15, 2012 | dropped | 021-113471 |
| RPI INTERNATIONAL PARTNERS 2019, LP | Private Equity Fund | $20.2M | Mar 28, 2024 | 2 | Mar 27, 2020 | reported | 021-360176 |
| ROYALTY PHARMA US PARTNERS 2008, LP | Private Equity Fund | $1.5M | Mar 30, 2021 | 9 | Feb 15, 2012 | dropped | 021-123404 |
| ROYALTY PHARMA CAYMAN PARTNERS 2008, LP | Private Equity Fund | $724,936 | Mar 30, 2021 | 2 | Feb 15, 2012 | dropped | n/a |
| ROYALTY PHARMA CAYMAN HOLDINGS 2008, LP | Private Equity Fund | $724,936 | Mar 30, 2021 | 7 | Feb 15, 2012 | dropped | 021-123405 |
| ROYALTY PHARMA SELECT | Private Equity Fund | $0 | Mar 28, 2024 | 0 | Apr 29, 2021 | reported | 021-123405 |
| Owner | Title | Ownership code | Control person | Acquired | First seen | Last seen |
|---|---|---|---|---|---|---|
| COYNE, TERRANCE, PATRICK | CHIEF FINANCIAL OFFICER | Na | yes | 03/2019 | Mar 29, 2019 | Mar 28, 2024 |
| LEGORRETA, PABLO, GERARDO | CHIEF EXECUTIVE OFFICER AND MANAGING MEMBER | D | yes | 08/2003 | Feb 15, 2012 | Mar 28, 2024 |
| LLOYD, GEORGE, WINGATE | EXECUTIVE VICE PRESIDENT AND CHIEF LEGAL OFFICER | Na | yes | 07/2011 | Feb 15, 2012 | Mar 28, 2024 |
| RP MIP HOLDINGS LLC | Member | C | yes | 01/2024 | Jan 31, 2024 | Mar 28, 2024 |
| URIST, MARSHALL, JONATHAN | EXECUTIVE VICE PRESIDENT, HEAD OF RESEARCH AND INVESTMENTS | Na | yes | 04/2022 | Jan 31, 2024 | Mar 28, 2024 |
| ERB, DOUGLAS, PETER | CHIEF ADMINISTRATIVE OFFICER | Na | no | 12/2014 | Dec 11, 2014 | Mar 28, 2024 |
| MCGIVERN, ARTHUR, RICHARD | EXECUTIVE VICE PRESIDENT AND GENERAL COUNSEL | Na | no | 10/2022 | Mar 31, 2023 | Mar 28, 2024 |
| RUBIN, CAROLYN, JUDITH | CHIEF COMPLIANCE OFFICER | Na | no | 03/2022 | Mar 30, 2022 | Mar 28, 2024 |
| SCHNEIDER, ERIC, CORNELIUS | CHIEF TECHNOLOGY OFFICER | Na | no | 09/2023 | Jan 31, 2024 | Mar 28, 2024 |
| Related person | Type | Class on the graph | Its RAUM | Control | Common control | State |
|---|---|---|---|---|---|---|
| PHARMAKON ADVISORS, LP | n/a | Asset manager | $3.0B | N | yes | n/a |
| PHARMA MANAGEMENT (CAYMAN) LTD. | n/a | n/a | n/a | N | yes | n/a |
| PHARMACEUTICAL INVESTORS LP | n/a | n/a | n/a | N | yes | n/a |
| RPI EPA HOLDINGS, LP | n/a | n/a | n/a | N | yes | n/a |
| City | State | Country | Employees | Also broker-dealer |
|---|---|---|---|---|
| SAN FRANCISCO | CA | United States | 1 | no |
| Fiscal year | Filed | RAUM | Discretionary | Employees | Advisory staff | Offices | Private funds | Fund GAV |
|---|---|---|---|---|---|---|---|---|
| 2025 | Mar 31, 2026 | $2.1B | $2.1B | 2 | 1 | 0 | 1 | n/a |
| 2024 | Mar 31, 2025 | $18B | $18B | 90 | 44 | 1 | 3 | n/a |
| 2023 | Mar 28, 2024 | $18B | $18B | 86 | 43 | 1 | 4 | $3.1B |
| 2022 | Mar 31, 2023 | $16B | $16B | 75 | 31 | 0 | 4 | $3.2B |
| 2021 | Mar 30, 2022 | $18B | $18B | 67 | 25 | 0 | 4 | $3.7B |
| 2020 | Mar 30, 2021 | $30B | $30B | 46 | 19 | 0 | 16 | $16B |
| 2019 | Mar 27, 2020 | $19B | $19B | 29 | 16 | 0 | 16 | $31B |
| 2018 | Mar 29, 2019 | $16B | $16B | 19 | 13 | 0 | 13 | $28B |
| 2017 | Mar 29, 2018 | $16B | $16B | 10 | 10 | 0 | 14 | $28B |
| 2016 | Mar 30, 2017 | $15B | $15B | 20 | 9 | n/a | 12 | $26B |
| 2015 | Mar 30, 2016 | $15B | $15B | 16 | 9 | n/a | 12 | $27B |
| 2014 | Mar 31, 2015 | $13B | $13B | 23 | 9 | n/a | 12 | $21B |
| 2013 | Mar 31, 2014 | $9.1B | $9.1B | 20 | 10 | n/a | 12 | $13B |
| 2012 | Apr 1, 2013 | $8.6B | $8.6B | 19 | 9 | n/a | 12 | $16B |
| Latest fiscal year | RAUM | A year earlier | 1y change | Three years earlier | 3y CAGR | Employees | A year earlier | Offices | A year earlier |
|---|---|---|---|---|---|---|---|---|---|
| 2025 | $2.1B | $18B | -88.3% | $16B | -49.1% | 2 | 90 | 0 | 1 |